67 related articles for article (PubMed ID: 1578946)
21. Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group.
Ohno R; Kobayashi T; Tanimoto M; Hiraoka A; Imai K; Asou N; Tomonaga M; Tsubaki K; Takahashi I; Kodera Y
Cancer; 1993 Jun; 71(12):3888-95. PubMed ID: 8508355
[TBL] [Abstract][Full Text] [Related]
22. [Prognosis, treatment completion, and complications in nonresponders in the study AML-BFM87].
Kallage V; Müller JE; Zimmermann M; Beck JD; Ritter J; Creutzig U
Klin Padiatr; 1999; 211(4):250-9. PubMed ID: 10472559
[TBL] [Abstract][Full Text] [Related]
23. No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group.
Miyawaki S; Tanimoto M; Kobayashi T; Minami S; Tamura J; Omoto E; Kuriyama K; Hatake K; Saito K; Kanamaru A; Oh H; Ohtake S; Asou N; Sakamaki H; Yamada O; Jinnai I; Tsubaki K; Takeyama K; Hiraoka A; Matsuda S; Takahashi M; Shimazaki C; Adachi K; Kageyama S; Ohno R
Int J Hematol; 1999 Aug; 70(2):97-104. PubMed ID: 10497848
[TBL] [Abstract][Full Text] [Related]
24. Consolidation therapy without maintenance for acute non-lymphoblastic leukaemia.
Roberts MM; Juttner CA; Blunden RW; Horvath N; To LB; Ho JQ; Dart GW; Kimber RJ
Med J Aust; 1988 Feb; 148(4):181-3. PubMed ID: 3340044
[TBL] [Abstract][Full Text] [Related]
25. Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: data from the AML Cooperative Group.
Büchner T; Hiddemann W; Löffler G; Gassmann W; Maschmeyer G; Heit W; Hossfeld D; Weh H; Ludwig WD; Thiel E
Semin Hematol; 1991 Jul; 28(3 Suppl 4):76-9. PubMed ID: 1780757
[No Abstract] [Full Text] [Related]
26. Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997.
Cripe LD; Rader K; Tallman MS; Gordon MS; Paietta E; Bennett J; Neuberg D; Litzow MR; O'brien TE; Rowe JM
Leuk Res; 2006 Jul; 30(7):823-7. PubMed ID: 16413056
[TBL] [Abstract][Full Text] [Related]
27. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
28. Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial.
Archimbaud E; Fiere D; Treille-Ritouet D; Adeleine P; Guyotat D; Sebban C; Vuvan H; Viala JJ
Cancer Treat Rep; 1987 Jun; 71(6):571-4. PubMed ID: 3555788
[TBL] [Abstract][Full Text] [Related]
29. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
Berman E; Arlin ZA; Gaynor J; Miller W; Gee T; Kempin SJ; Mertelsmann R; Andreeff M; Reich L; Nahmias N
Leukemia; 1989 Feb; 3(2):115-21. PubMed ID: 2911205
[TBL] [Abstract][Full Text] [Related]
30. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
Farag SS; Ruppert AS; Mrózek K; Mayer RJ; Stone RM; Carroll AJ; Powell BL; Moore JO; Pettenati MJ; Koduru PR; Stamberg J; Baer MR; Block AW; Vardiman JW; Kolitz JE; Schiffer CA; Larson RA; Bloomfield CD
J Clin Oncol; 2005 Jan; 23(3):482-93. PubMed ID: 15534356
[TBL] [Abstract][Full Text] [Related]
31. [Improved treatment results in children with AML: Results of study AML-BFM 93].
Creutzig U; Berthold F; Boos J; Fleischhack G; Gadner H; Gnekow A; Graubner U; Henze G; Hermann J; Imbach P; Jürgens H; Kabisch H; Körholz D; Niemeyer CM; Reinhardt D; Reiter A; Ritter J; Spaar HJ; Zimmermann M;
Klin Padiatr; 2001; 213(4):175-85. PubMed ID: 11528551
[TBL] [Abstract][Full Text] [Related]
32. The impact of early intensive therapy on event-free survival (EFS) in children with acute myeloid leukemia (AML).
Weinstein H; Ravindranath Y; Krischer J; Steuber P; Civin C; Gresik M; Vietti T
Leukemia; 1992; 6 Suppl 2():52-4. PubMed ID: 1578941
[No Abstract] [Full Text] [Related]
33. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.
Mayer RJ; Davis RB; Schiffer CA; Berg DT; Powell BL; Schulman P; Omura GA; Moore JO; McIntyre OR; Frei E
N Engl J Med; 1994 Oct; 331(14):896-903. PubMed ID: 8078551
[TBL] [Abstract][Full Text] [Related]
34. Maintenance therapy in childhood acute myeloid leukemia.
Perel Y; Auvrignon A; Leblanc T; Michel G; Vannier JP; Dalle JH; Gandemer V; Schmitt C; Mèchinaud F; Lamagnere JP; Piguet Ch; Couillaud G; Pautard B; Baruchel A; Leverger G; ;
Ann Hematol; 2004; 83 Suppl 1():S116-9. PubMed ID: 15124700
[TBL] [Abstract][Full Text] [Related]
35. Treatment of older patients with AML.
Büchner T; Berdel WE; Wörmann B; Schoch C; Haferlach T; Schnittger S; Kern W; Aul C; Lengfelder E; Schumacher A; Reichle A; Staib P; Balleisen L; Eimermacher H; Grüneisen A; Rasche H; Sauerland MC; Heinecke A; Mesters RM; Serve HL; Kienast J; Hiddemann W
Crit Rev Oncol Hematol; 2005 Nov; 56(2):247-59. PubMed ID: 16246568
[TBL] [Abstract][Full Text] [Related]
36. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
de Witte T; Suciu S; Peetermans M; Fenaux P; Strijckmans P; Hayat M; Jaksic B; Selleslag D; Zittoun R; Dardenne M
Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266
[TBL] [Abstract][Full Text] [Related]
37. Long-term survival of patients with acute myeloid leukemia: updated results from two trials evaluating postinduction chemotherapy.
Bloomfield CD; Herzig GP; Peterson BA; Wolff SN
Cancer; 1997 Dec; 80(11 Suppl):2186-90. PubMed ID: 9395032
[TBL] [Abstract][Full Text] [Related]
38. SAB--a promising new treatment to improve remission rates in AML in the elderly?
Wheatley K
Br J Haematol; 2002 Aug; 118(2):432-3. PubMed ID: 12139727
[TBL] [Abstract][Full Text] [Related]
39. Value of maintenance therapy with chemotherapy or interferon during remission of acute myeloid leukaemia.
Palva IP; Almqvist A; Elonen E; Hänninen A; Jouppila J; Järventie G; Koivunen E; Kätkä K; Lahtinen R; Oivanen T
Eur J Haematol; 1991 Sep; 47(3):229-33. PubMed ID: 1915807
[TBL] [Abstract][Full Text] [Related]
40. Postinduction and preremission chemotherapy alternatives for adult AML: three multicenter studies of the AML Cooperative Group.
Büchner T; Hiddemann W; Urbanitz D; Kreutzmann H; Maschmeyer G; Wendt F; Kuse R; Mohr A; Gassmann W; Löffler H
Haematol Blood Transfus; 1987; 30():57-63. PubMed ID: 3305221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
